Eevia Health Oy addresses global health problems with innovative, bioactive extracts from plant material. Standardized extracts with well researched positive effects for human health are sold B2B as ingredients to dietary supplement, medical food, pharmaceutical and cosmetic brand holders globally.
Eevia Health has 60 customers in 16 countries. Since it was founded in March 2017, Eevia’s sales have grown rapidly with an average Q-on-Q growth of 35% to 1.6 M€ in 2019. Its products address eye-health conditions (retinopathy), low grade inflammation and metabolic conditions in humans.
Eevia Health employs 11 experts and owns a modern manufacturing site in Finland with state-of-the-art green chemistry extraction and enrichment technologies. The team and a network of external advisors, board members and scientific partners constitute a small life science start-up. Over 3.5 M€ has been invested in equity from 50 shareholders. Per 08.01.2020 the company has not acquired any debt nor received any public funding.
Eevia Health is compliant with current good manufacturing practice (cGMP) and has been certified and audited by Finnish and foreign authorities, such as US FDA, Inspecta (ISO 22 000) etc. The management has a unique competence mix of technology and business, and a track record of starting and building similar companies. We are working with national and international partners on research, product development and sales of branded products. Carefully selected distributors work in key markets, for instance Barrington Nutritionals (US) and Ingredient Plus (Australia). A new cutting-edge polyphenol extract, Retinari™, addressing Age-Related Macular Degeneration (AMD), an irreversible eye-condition, has been developed by Eevia Health Oy over the last 3 years. Eevia Health Oy is the owner of the Retinari™ and the holder of the product IPR.